{
    "nct_id": "NCT06088199",
    "official_title": "A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis",
    "inclusion_criteria": "* Participants must have a weight of â‰¥ 20 kg.\n* Participant must have an age and sex specific BMI value no lower in range than the fifth percentile on the growth chart for children and adolescents.\n* Participant is able to swallow the study medication tablet.\n* Diagnosis of chronic plaque psoriasis for at least 6 months prior to screening.\n* Has mild to moderate plaque psoriasis at screening and Study Visit 1 as defined by:\n* Psoriasis Area Severity Index score 2-15,\n* Body surface area 2-15%, and\n* Static Physician Global Assessment score of 2-3 (mild to moderate)\n* Disease inadequately controlled by or inappropriate for topical therapy for psoriasis.\nHealthy volunteers allowed\nMust have minimum age of 6 Years\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* Guttate, erythrodermic, or pustular psoriasis at screening and Study Day 1.\n* Psoriasis flare or rebound within 4 weeks prior to screening.\n* Active tuberculosis (TB) or a history of incompletely treated TB per local guidelines.\n* History of recurrent significant infections.\n* Active infection or infection treated with antibiotic treatment within 14 days of Study Day 1.\n* Any history of or active malignancy or myeloproliferative or lymphoproliferative disease.\n* Current use of the following therapies that may have a possible effect on psoriasis:\n* Conventional systemic therapy for psoriasis within 28 days prior to Study Day 1 (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters).\n* Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 28 days prior to Study Day 1.\n* Biologic therapy:\n\n  * Etanercept (or biosimilar) treatment 28 days prior to Study Day 1\n  * Adalimumab (or biosimilar) treatment 10 weeks prior to Study Day 1\n  * Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to Study Day 1\n  * Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) within 24 weeks prior to Study Day 1.\n* Use of tanning booths or other ultraviolet light sources.\n* Answer \"Yes\" to any question on the Columbia-Suicide Severity Rating Scale during screening or at Study Day 1.\n* Female participant of childbearing potential with a positive pregnancy test assessed at screening and/or Study Day 1 by a serum and/or urine pregnancy test.",
    "miscellaneous_criteria": ""
}